Opko Health (NASDAQ:OPK) Stock Price Down 6.3%

Opko Health Inc. (NASDAQ:OPK) fell 6.3% during mid-day trading on Friday . The stock traded as low as $1.89 and last traded at $1.94, 5,591,717 shares changed hands during trading. An increase of 17% from the average session volume of 4,776,376 shares. The stock had previously closed at $2.07.

Several research firms recently issued reports on OPK. ValuEngine upgraded shares of Opko Health from a “sell” rating to a “hold” rating in a research report on Thursday. Zacks Investment Research upgraded shares of Opko Health from a “hold” rating to a “buy” rating and set a $2.75 price target on the stock in a research report on Tuesday, April 30th. One analyst has rated the stock with a hold rating and four have given a buy rating to the company’s stock. Opko Health presently has an average rating of “Buy” and an average price target of $9.25.

The company has a debt-to-equity ratio of 0.13, a quick ratio of 0.99 and a current ratio of 1.10. The stock has a market cap of $1.27 billion, a price-to-earnings ratio of -7.76 and a beta of 2.15. The company has a 50-day moving average of $2.14.

Opko Health (NASDAQ:OPK) last posted its quarterly earnings results on Tuesday, May 7th. The biotechnology company reported ($0.14) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.06) by ($0.08). Opko Health had a negative return on equity of 9.86% and a negative net margin of 19.92%. The firm had revenue of $222.50 million for the quarter, compared to analyst estimates of $241.27 million. During the same quarter in the prior year, the business posted ($0.08) EPS. The business’s revenue was down 12.7% on a year-over-year basis. On average, equities analysts expect that Opko Health Inc. will post -0.42 earnings per share for the current fiscal year.

In related news, Director Richard C. Pfenniger, Jr. bought 30,000 shares of the business’s stock in a transaction on Wednesday, May 22nd. The shares were purchased at an average price of $2.05 per share, for a total transaction of $61,500.00. Following the completion of the transaction, the director now directly owns 250,000 shares of the company’s stock, valued at approximately $512,500. The acquisition was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, CEO Phillip Md Et Al Frost bought 907,000 shares of the business’s stock in a transaction on Wednesday, May 8th. The stock was bought at an average price of $2.11 per share, for a total transaction of $1,913,770.00. Following the transaction, the chief executive officer now directly owns 3,068,951 shares of the company’s stock, valued at $6,475,486.61. The disclosure for this purchase can be found here. Insiders acquired 2,545,250 shares of company stock worth $5,202,900 in the last 90 days. Company insiders own 42.25% of the company’s stock.

Institutional investors have recently modified their holdings of the business. Piedmont Investment Advisors Inc. acquired a new position in shares of Opko Health during the first quarter worth $27,000. Mercer Global Advisors Inc. ADV acquired a new position in shares of Opko Health during the first quarter worth $39,000. Meeder Asset Management Inc. lifted its holdings in shares of Opko Health by 58.7% during the first quarter. Meeder Asset Management Inc. now owns 13,102 shares of the biotechnology company’s stock worth $35,000 after purchasing an additional 4,846 shares during the period. Eqis Capital Management Inc. acquired a new position in shares of Opko Health during the second quarter worth $33,000. Finally, B. Riley Wealth Management Inc. acquired a new position in shares of Opko Health during the first quarter worth $39,000. Hedge funds and other institutional investors own 25.51% of the company’s stock.

Opko Health Company Profile (NASDAQ:OPK)

OPKO Health, Inc, a healthcare company, engages in the diagnostics and pharmaceuticals business in the United States, Ireland, Chile, Spain, Israel, Mexico, and internationally. The company's Diagnostics segment operates BioReference Laboratories, a clinical laboratory that offers laboratory testing services.

Featured Article: Why do corrections happen?

Receive News & Ratings for Opko Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Opko Health and related companies with MarketBeat.com's FREE daily email newsletter.